Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Ventyx Biosciences (Nasdaq: VTYX) presented new 52-week results from the Phase 2 trial of VTX002 (tamuzimod) in ulcerative colitis at UEG Week 2024. The late-breaking abstract highlighted high rates of clinical and endoscopic remission among long-term extension (LTE) completers at Week 52. CEO Raju Mohan emphasized the data's reinforcement of tamuzimod's potential best-in-class profile as an S1P1R modulator in ulcerative colitis, with a possibly best-in-disease safety profileamong oral UC therapies. The company believes these results position tamuzimod as the backbone of future combination therapies for UC. The presentation, delivered by Dr. Silvio Danese, focused on the efficacy and safety of tamuzimod through 52 weeks in moderately to severely active ulcerative colitis.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
3078 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    2996Followers
    109Following
    31KVisitors
    Follow